stock-detail (BPMC)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

4/24/2017 06:17 pm

Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

3/29/2017 10:05 pm

[PR Newswire] - CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering. Raymond James is acting as co-manager for the offering. The offering is expected to close on or about April 4, 2017, subject to the satisfaction of customary closing conditions. A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with and declared effective by the Securities and Exchange Commission (SEC).

Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

3/29/2017 11:03 am

[PR Newswire] - CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an underwritten public offering of $150,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional of $22,500,000 in shares of its common stock in connection with the public offering. Blueprint Medicines expects to use the net proceeds of the offering to fund clinical trials for BLU-285 in GIST and SM, to fund clinical trials for BLU-554 in HCC, to fund the completion of its current Phase 1 clinical trial for BLU-667 in non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors and the initiation of additional clinical trials for BLU-667 in RET-driven cancers, and the balance, if any, to fund working capital, and other general corporate purposes, including ongoing research and pre-commercial planning activities.

Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences

3/27/2017 08:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...

Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667

3/20/2017 08:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 20, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of BLU-667, an investigational RET inhibitor for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors that harbor a RET alteration. "By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "This continued progress underscores our commitment to build Blueprint Medicines into a sustainable company.

Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results

3/9/2017 12:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 9, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...